


## CB30865

<b>Cat. No.:</b>	HY-14373		
<b>CAS No.:</b>	206275-15-2		
<b>Molecular Formula:</b>	C <sub>26</sub> H <sub>22</sub> BrN <sub>5</sub> O <sub>2</sub>		
<b>Molecular Weight:</b>	516.39		
<b>Target:</b>	NAMPT		
<b>Pathway:</b>	Metabolic Enzyme/Protease		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 33.33 mg/mL (64.54 mM; Need ultrasonic)

Solvent	Mass	Concentration		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	1.9365 mL	9.6826 mL	19.3652 mL
	5 mM	0.3873 mL	1.9365 mL	3.8730 mL
	10 mM	0.1937 mL	0.9683 mL	1.9365 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

CB30865 (ZM 242421) is a nicotinamide phosphoribosyltransferase (Nampt) inhibitor, with potent cytotoxicity. CB30865 is highly potent against a variety of human tumour cell lines (IC<sub>50</sub> values in the 1-10 nM range)<sup>[1][2]</sup>.

#### In Vitro

CB30865 exhibits cytotoxicity due to NAD reduction via Nampt inhibition<sup>[1]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Fleischer TC, et al. Chemical proteomics identifies Nampt as the target of CB30865, an orphan cytotoxic compound. *Chem Biol.* 2010 Jun 25;17(6):659-664.
- [2]. Skelton LA, et al. Cell cycle effects of CB30865, a lipophilic quinazoline-based analogue of the antifolate thymidylate synthase inhibitor ICI 198583 with an undefined mechanism of action. *Cytometry.* 1998 Sep 1;33(1):56-66.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA